Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors.

Biological Assembly 2  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 2 assigned by authors.

Macromolecule Content

• Total Structure Weight: 44107.31 
• Atom Count: 3058 
• Residue Count: 376 
• Unique protein chains: 1

1XDD

X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution

• DOI: 10.2210/pdb1XDD/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Homo sapiens
• Expression System: Escherichia coli


• Deposited: 2004-09-06 Released: 2004-09-21 
• Deposition Author(s): Weitz-Schmidt, G., Welzenbach, K., Dawson, J., Kallen, J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.2 Å
• R-Value Free: 0.206 
• R-Value Work: 0.161 

Literature

Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo

Weitz-Schmidt, G., Welzenbach, K., Dawson, J., Kallen, J.

(2004) J.Biol.Chem. 279: 46764-46771

• PubMed: 15304496 
• DOI: 10.1074/jbc.M407951200
• Primary Citation of Related Structures:  
  1XDG


• PubMed Abstract: 
  

The integrin lymphocyte function-associated antigen-1 (LFA-1) (alphaLbeta2; CD11a/CD18) plays an important role in leukocyte migration and T cell activation. LFA-1 is inhibited by the cholesterol-lowering drug lovastatin, which binds to an allosteric site of the alphaL I domain termed the lovastatin site (L-site). Here we report for the first time the x-ray structures of the LFA-1 I domain complexed with derivatives of lovastatin optimized for LFA-1 inhibition. This analysis identified two new subpockets within the L-site occupied by chemical groups of the statin derivatives but not by lovastatin itself. Occupancy of these L-site subpockets led to distinct conformational changes in LFA-1, which were detectable by an epitope-monitoring assay. We utilized this assay to demonstrate improved LFA-1 inhibition in human blood in vitro and in blood samples from treated animals ex vivo. Moreover, we demonstrate that the novel lovastatin-derived LFA-1 inhibitor LFA878 exhibits potent anti-inflammatory effects in carrageenan-induced rat paw edema. In summary, the findings reported here extend the understanding of LFA-1 inhibition at the molecular level, allow for the identification and design of LFA-1 inhibitors of further enhanced potency, and support the expectation that LFA-1 inhibitors binding to the L-site will be of therapeutic value in treating inflammatory diseases.

---

Organizational Affiliation: 

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Integrin alpha-L	A, B	188	Homo sapiens	Mutation(s): 0  Gene Names: ITGAL (CD11A)
Find proteins for P20701 (Homo sapiens) Go to Gene View: ITGAL Go to UniProtKB:  P20701

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
AAY	A, B	8-[2-((2S)-4-HYDROXY-1-{[5-(HYDROXYMETHYL)-6-METHOXY-2-NAPHTHYL]METHYL}-6-OXOPIPERIDIN-2-YL)ETHYL]-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2-METHYLBUTANOATE LFA703 C37 H49 N O6 WPVRNXUYVXQXPY-YFAYRSKXSA-N
MG	A, B	MAGNESIUM ION Mg JLVVSXFLKOJNIY-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
AAY	IC50: 200 nM BINDINGMOAD
AAY	IC50: 200 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.2 Å
• R-Value Free: 0.206 
• R-Value Work: 0.161 
• Space Group: P 4₃ 2₁ 2

Unit Cell:

Length (Å)	Angle (°)
a = 116.700	α = 90.00
b = 116.700	β = 90.00
c = 82.800	γ = 90.00

Software Package:

Software Name	Purpose
REFMAC	refinement
X-PLOR	phasing
SCALEPACK	data scaling
DENZO	data reduction

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2004-09-06 
• Released Date: 2004-09-21 
• Deposition Author(s): Weitz-Schmidt, G., Welzenbach, K., Dawson, J., Kallen, J.

Revision History 

• Version 1.0: 2004-09-21
  Type: Initial release
• Version 1.1: 2008-04-30
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance
• Version 1.3: 2013-02-20
  Type: Database references
• Version 1.4: 2014-11-12
  Type: Structure summary